Leerink Partners analyst Stephanie Davis maintained a Buy rating on Teladoc (NYSE:TDOC) on Wednesday, setting a price target of $266, which is approximately 62.98% above the present share price of $163.21.
Davis expects Teladoc to post earnings per share (EPS) of $0.00 for the second quarter of 2021.
The current consensus among 23 TipRanks analysts is for a Moderate Buy rating of shares in Teladoc, with an average price target of $243.68.
The analysts price targets range from a high of $300 to a low of $185.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $453.68 million and a net profit of -$78.36 million. The company's market cap is $25.2 billion.
According to TipRanks.com, Leerink Partners analyst Stephanie Davis is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 23.2% and a 62.62% success rate.
Teladoc Health, Inc. is a multinational telemedicine and virtual healthcare company. The company provides telehealth solutions, expert medical services, medical opinions, artificial intelligence and analytics, behavioral health solutions, guidance and support, and platform and program services.